Ajinomoto and RIBOMIC Revolutionize Antibody Drugs with Extended Half-Life Technology
Ajinomoto Co., Inc. and RIBOMIC Inc. have collaborated on a groundbreaking technology that extends the half-life of nucleic acid aptamers, potentially transforming the pharmaceutical industry and marking a new era for Ajinomoto.
2 minutes to read